Cargando…

CSF p-tau231: A biomarker for early preclinical Alzheimer?

Detalles Bibliográficos
Autor principal:	Suárez-Calvet, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919211/ https://www.ncbi.nlm.nih.gov/pubmed/35290829 http://dx.doi.org/10.1016/j.ebiom.2022.103936

Ejemplares similares

CSF P-tau 231 as Biomarker in Alzheimer's Disease
por: Mukherjee, Adreesh, et al.
Publicado: (2022)

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
por: Milà-Alomà, Marta, et al.
Publicado: (2022)

Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
por: Milà-Alomà, Marta, et al.
Publicado: (2022)

Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts
por: Lantero-Rodriguez, Juan, et al.
Publicado: (2023)

P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease
por: Lantero‐Rodriguez, Juan, et al.
Publicado: (2021)

Accumulation of pTau231 at the Postsynaptic Density in Early Alzheimer’s Disease
por: Lilek, Jaclyn, et al.
Publicado: (2023)

Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays
por: Leuzy, Antoine, et al.
Publicado: (2021)

Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology
por: Ashton, Nicholas J., et al.
Publicado: (2021)

(18)F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected
por: Suárez‐Calvet, Marc, et al.
Publicado: (2020)

CSF sTREM2 in delirium—relation to Alzheimer’s disease CSF biomarkers Aβ42, t-tau and p-tau
por: Henjum, Kristi, et al.
Publicado: (2018)

Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease
por: Ashton, Nicholas J., et al.
Publicado: (2022)

Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease
por: Fossati, Silvia, et al.
Publicado: (2019)

Brain alterations in the early Alzheimer’s continuum with amyloid-β, tau, glial and neurodegeneration CSF markers
por: Salvadó, Gemma, et al.
Publicado: (2022)

CSF p-Tau levels in the prediction of Alzheimer's disease
por: Kandimalla, Ramesh J. L., et al.
Publicado: (2013)

Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum
por: Milà‐Alomà, Marta, et al.
Publicado: (2020)

Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s Disease
por: Meredith Jr., Jere E., et al.
Publicado: (2013)

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
por: Ossenkoppele, Rik, et al.
Publicado: (2021)

Fluorescent Aptasensor and Colorimetric Aptablot for p-tau231 Detection: Toward Early Diagnosis of Alzheimer’s Disease
por: Phan, Le Minh Tu, et al.
Publicado: (2022)

CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease
por: Horie, Kanta, et al.
Publicado: (2023)

Characterization of Alzheimer’s tau biomarker discordance using plasma, CSF, and PET
por: Guo, Yu, et al.
Publicado: (2021)

CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET: A Cross-sectional Study
por: Milà-Alomà, Marta, et al.
Publicado: (2021)

P-tau231 as a Diagnostic Biomarker for Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis
por: Nabizadeh, Fardin, et al.
Publicado: (2022)

Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology
por: Suárez-Calvet, Marc, et al.
Publicado: (2019)

Concatenating plasma p-tau to Alzheimer’s disease
por: Tijms, Betty M, et al.
Publicado: (2021)

Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring
por: Ashton, Nicholas J., et al.
Publicado: (2022)

Comparing (18)F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease
por: Mattsson, Niklas, et al.
Publicado: (2018)

CSF neurogranin or tau distinguish typical and atypical Alzheimer disease
por: Wellington, Henrietta, et al.
Publicado: (2018)

CSF p-tau as a potential cognition impairment biomarker in ALS
por: Gong, Zhongying, et al.
Publicado: (2022)

Is phosphorylated tau a good biomarker of synapse pathology in Alzheimer’s disease?
por: Saura, Carlos A, et al.
Publicado: (2023)

CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
por: Barthélemy, Nicolas R., et al.
Publicado: (2023)

CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status
por: Dong, Ruocheng, et al.
Publicado: (2021)

Novel CSF tau biomarkers can be used for disease staging of sporadic Alzheimer’s disease
por: Salvadó, Gemma, et al.
Publicado: (2023)

Normalization of CSF pTau measurement by Aβ(40) improves its performance as a biomarker of Alzheimer’s disease
por: Guo, Tengfei, et al.
Publicado: (2020)

CSF GAP-43 as a biomarker of synaptic dysfunction is associated with tau pathology in Alzheimer’s disease
por: Qiang, Qiang, et al.
Publicado: (2022)

Ultrasensitive tau biosensor cells detect no seeding in Alzheimer’s disease CSF
por: Hitt, Brian D., et al.
Publicado: (2021)

Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231
por: Bayoumy, Sherif, et al.
Publicado: (2021)

β-Amyloid–Dependent and –Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease
por: Kumar, Atul, et al.
Publicado: (2022)

Diurnal oscillation of CSF Aβ and other AD biomarkers
por: Lucey, Brendan P., et al.
Publicado: (2017)

Harmonization of CSF and imaging biomarkers for Alzheimer’s disease biomarkers: need and practical applications for genetics studies and preclinical classification
por: Timsina, Jigyasha, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v4fe2ighb5idu46f3d9lh2joef